Fig. 9

Inactivation of pathogenic α-syn derived from brains of MSA patients. a Sarkosyl-insoluble fractions prepared from 2 MSA cases (MSA-2 Pu and MSA-3 FC) after various inactivation treatments were analyzed by immunoblotting with anti-syn 102–116 antibody. b Sarkosyl-insoluble fractions extracted from MSA brains after inactivation treatments (2 μl) were introduced into SH-SY5Y cells transiently expressing human WT α-syn. Immunoblot analyses of sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble fractions (sup) extracted from mock-transfected cells or cells transfected with pathogenic α-syn derived from MSA brains and treated with 1% SDS for 1 h at room temperature, boiling, autoclaving (AC) at 120 °C with or without 1% SDS or AC at 134 °C with or without 1% SDS are shown. Phosphorylated α-syn was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-syn 131–140 antibody. c, Quantification of immunoblot analyses shown in b. The results are expressed as means ± SEM (n = 3). “No treatment” was taken as 100%. One-way ANOVA with Dunnett’s post hoc test were used for multiple comparisons to no treatment, *P < 0.05; **P < 0.01